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The neplanocin A analogs, 3-deazaneplanocin A, 9-(trans-2',trans-3'-dihydroxycyclopent-4'-enyl)adenine
(DHCA), and 9-(trans-2',trans-3'-dihydroxycyclopent-4'-enyl)-3-deazaadenine (DHCDA), all potent inhibitors
of S-adenosylhomocysteine (AdoHcy) hydrolase, were studied for their broad-spectrum antiviral potential.
3-Deazaneplanocin A, DHCA, and DHCDA proved specifically effective against vesicular stomatitis virus,
vaccinia virus, parainfluenza virus, reovirus, and rotavirus. Their selectivity was greater than that of
neplanocin A, particularly against vesicular stomatitis virus and rotavirus. As could be expected from
adenosine analogs that are directly targeted at AdoHcy hydrolase, 3-deazaneplanocin A, DHCA, and DHCDA
were fully active in adenosine kinase-deficient cells, implying that their activity did not depend on phosphor-
ylation by adenosine kinase. None of the AdoHcy hydrolase inhibitors showed selective activity against human
immunodeficiency virus (type 1). 3-Deazaneplanocin A at a dose of 0.5 mg/kg per day conferred marked
protection against a lethal infection of newborn mice with vesicular stomatitis virus.
Neplanocin A is a potent antiviral agent active against a
broad spectrum of viruses belonging to the Poxviridae,
Rhabdoviridae, Paramyxoviridae, and Reoviridae (6). It is
particularly effective against vaccinia virus, vesicular stoma-
titis virus, parainfluenza virus, measles virus, reovirus (6),
and human rotavirus (20). Neplanocin A is a potent inhibitor
of S-adenosylhomocysteine (AdoHcy) hydrolase, a key en-
zyme in transmethylation reactions depending on S-adenos-
ylmethionine as the methyl donor (2). As such, transmethy-
lation reactions play an important role in the maturation
(e.g., 5' capping) of viral mRNA, and AdoHcy hydrolase has
been considered to be an important target enzyme for
broad-spectrum antiviral agents (7). In fact, a close correla-
tion has been found between the antiviral effects of a series
of adenosine analogs, including neplanocin A, and their
inhibitory effects on AdoHcy hydrolase (4, 9).
Although antivirally active at concentrations which are
well below its toxicity threshold for the host cells (6),
neplanocin A is definitely cytotoxic for a number of tumor
cells (18, 24). This cytotoxicity may be attributed to the fact
that the compound is readily phosphorylated to its triphos-
phate (1, 24), which then interferes with host-cell RNA
synthesis (18). Neplanocin A triphosphate could be further
metabolized to S-neplanocylmethionine (14, 19), and this
metabolite may also play an important role in the cytotoxic
action of the compound (14). If the hypothesis is correct that
the antiviral action of neplanocin A is due to an inhibitory
effect of the compound per se on AdoHcy hydrolase,
whereas its cytotoxic action depends upon phosphorylation
to the corresponding triphosphate, it should be possible to
design neplanocin A analogs that are endowed with antiviral
properties while lacking cytotoxicity, thus achieving a better
therapeutic index than that of neplanocin A itself.
* Corresponding author.
For this reason, 3-deazaneplanocin A and the "decapi-
tated" analogs of neplanocin A and 3-deazaneplanocin A,
referred to as DHCA [9-(trans-2',trans-3'-dihydroxycyclo-
pent-4'-enyl)adenine] and DHCDA [9-(trans-2',trans-3'-di-
hydroxycyclopent-4'-enyl)-3-deazaadenine], were synthe-
sized (3, 15, 22). Both DHCA and DHCDA were indeed
more selective in their activity against vaccinia virus than
neplanocin A was (16). In the initial study, the activity
against only one virus (vaccinia) was determined and 3-
deazaneplanocin A was not included for comparison. We
have now extended these studies to a broad range of DNA
and RNA viruses. In addition to DHCA, DHCDA, and
neplanocin A, we included in our investigation 3-deazane-
planocin A, which is also assumed to be a potent inhibitor of
AdoHcy hydrolase but with a lower degree of cytotoxicity
than neplanocin A (13, 15). The structural formulae of the
compounds are depicted in Fig. 1. The compounds were
examined for both antiviral and antimetabolic activities in a
variety of cell systems. The therapeutic potential of these
compounds was also assessed in vivo by using newborn mice
infected with a lethal dose of vesicular stomatitis virus.
MATERIALS AND METHODS
Test compounds. Neplanocin A (MW 263.3) was obtained
from Toyo Jozo Co. (Tagata-gun, Shizuoka-ken, Japan)
through the courtesy of J. Murase. 3-Deazaneplanocin A
(MW 262.2) was synthesized as previously described (27)
from the optically active cyclopentenyl moiety. DHCA and
DHCDA (Mws 233.2 and 232.2) were synthesized by proce-
dures described previously (3). Carbocyclic 3-deazaade-
nosine (C-c3Ado) (MW 300.7) (21) was obtained from J. A.
Montgomery (Kettering-Meyer Laboratory, Southern Re-
search Institute, Birmingham, Ala.). Tubercidin (MW 266.3)
was purchased from Sigma Chemical Company (St. Louis,
Mo.). Xylotubercidin (12), sangivamycin, and toyocamycin
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FIG. 1. Structural formulae of neplanocin A, 3-deazaneplanocin
A, and their decapitated analogs DHCA and DHCDA.
(8) (Mws 266.3, 309.3, and 291.3, respectively) were ob-
tained from M. J. Robins (Department of Chemistry, Uni-
versity of Alberta, Edmonton, Alberta, Canada; now at the
Chemistry Department, Brigham Young University, Provo,
Utah). Cordycepin (Mw 251.2) was from Sigma Chemical
Company. Stock solutions of the compound were prepared
in phosphate-buffered saline (PBS) or cell culture medium at
a concentration of 1 mg/ml. At this concentration, all com-
pounds were soluble in aqueous medium.
Viruses and cells. The origin of the viruses (herpes simplex
virus type 1 KOS and type 2 G, vaccinia virus, vesicular
stomatitis virus, coxsackievirus B4, poliovirus type 1,
parainfluenza virus type 3, reovirus type 1, Sindbis virus,
and Semliki Forest virus) and cells (primary rabbit kidney
[PRK], HeLa, and African green monkey kidney [Vero]) has
been described previously (6). For further details on the
rotavirus MO strain (subgroup 2, serotype 3) and MA 104
cells (derived from embryonic rhesus monkey kidney), see
Kitaoka et al. (20). Human immunodeficiency virus type 1
(HIV-1) was obtained from the supernatant of a persistently
HIV-1-infected H9 cell line (H9/HTLV-IIIB) which was
kindly provided by R. C. Gallo (National Cancer Institute,
Bethesda, Md.). Human T-lymphocyte MT-4 cells were
kindly supplied by N. Yamamoto (Yamaguchi University,
Yamaguchi, Japan). The cells were mycoplasma free. The
AK' (adenosine kinase-positive) B-mix K-44/6 (Rous sar-
coma virus-transformed) rat cells were originally obtained
from J. Svoboda (Institute of Experimental Biology and
Genetics, Prague, Czechoslovakia) (26). The AK- (adeno-
sine kinase-deficient) cell line (clone D-4) was derived from
the AK' parent line by selection of a cell population that
remained resistant to an ara-A (vidarabine) concentration
that was 100-fold greater than that tolerated by the AK'
cells (25; N. B. Katlama, Ph.D. thesis, University of Mich-
igan, Ann Arbor, 1984). Both the AK+- and AK--B-mix
K-44/6 cell lines were devoid of adenosine deaminase activ-
ity (25).
Inhibition of virus-induced cytopathogenicity. Confluent
cell monolayers in microtiter trays were inoculated with 100
CCID50 (50% confluent cell infective dose; 1 CCID50 corre-
sponds to the virus stock dilution that proved infective for
50% of the cell cultures). After 1 h of virus adsorption to the
cells, residual virus was removed and replaced by cell
culture medium (Eagle minimum essential medium) contain-
ing 3% fetal calf serum (horse serum for the experiments
with the AK+- and AK--B-mix K-44/6 cells) and various
concentrations of the test compounds. Viral cytopathogenic-
ity was recorded as soon as it reached completion in the
untreated virus-infected cell cultures, i.e., at 1 to 2 days for
vesicular stomatitis virus; at 2 days for Semliki Forest virus,
coxsackievirus B4, and poliovirus type 1; at 2 to 3 days for
vaccinia virus, herpes simplex virus types 1 and 2, and
Sindbis virus; and at 6 to 7 days for reovirus type 1 and
parainfluenza virus type 3. The antiviral activity of the
compounds was expressed as the concentration required to
inhibit viral cytopathogenicity by 50%.
Inhibition of rotavirus replication. Virus yield was mea-
sured as described previously (20), and the antiviral activity
of the compounds was expressed as the concentration re-
quired to achieve a 90% reduction in the 24-h virus yield.
Inhibition of HIV replication. The method of the antiretro-
viral assays has been described previously (23). Briefly,
MT-4 cells (5 x 105/ml) were suspended in fresh culture
medium and infected with HIV-1 at 200 CCID50 per ml of cell
suspension. Then, 100 1jl of the infected cell suspension was
mixed with 100 Il of the appropriate dilution of test com-
pound, transferred to microplate wells, and further incu-
bated at 37°C for 5 days. Then the number of viable cells was
determined for both virus-infected and mock-infected cell
cultures.
Cytotoxicity. Cytotoxicity measurements were based on
the following parameters: (i) alteration of normal cell mor-
phology, (ii) inhibition of host-cell protein synthesis, and (iii)
reduction in the number of viable cells. To evaluate cell
morphology (i), confluent cell cultures which had not been
infected but were treated with various concentrations of the
test compounds were incubated in parallel with the virus-
infected cell cultures and examined microscopically at the
same time as viral cytopathogenicity was recorded for the
virus-infected cell cultures. A disruption of the cell mono-
layers, e.g., rounding up or detachment of the cells, was
considered to be evidence for cytotoxicity. To determine
host-cell protein synthesis (ii), the cells were seeded in
96-well microtest plates (Falcon; Becton Dickinson and Co.,
Lincoln Park, N.J.) at a density of 20,000 cells per well.
After 24 h of incubation in a humidified, C02-controlled
atmosphere at 37°C, the cells were refed with fresh Eagle
minimum essential medium containing 3% fetal calf serum
and the appropriate concentration of the test compound.
After 72 h of incubation at 37°C, the cells were pulse-labeled
for 3 h with L-[4,5-3H]leucine (64 Ci/mmol; 0.5 ,uCi per well)
(Amersham, Buckinghamshire, England). After the pulse-
label period, the cells were washed with PBS and fixed with
methanol. The proteins were precipitated with 10% tri-
chloroacetic acid, and the trichloroacetic acid pellet was
solubilized overnight with 1 N NaOH. The solubilized
samples were then transferred to scintillation vials and, upon
addition of scintillation fluid (Instafluor and Soluene; Pack-
ard Instruments, Groningen, The Netherlands), analyzed for
radioactivity. Inhibition of the radioactivity counts by 50%
was taken as the endpoint for cytotoxicity. To determine cell
viability (iii), the cells were enumerated by a trypan blue dye
exclusion assay (20), and the minimum cytotoxic concentra-
tion was defined as the concentration of test compound
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TABLE 1. Antiviral activity and cytotoxicity in PRK cell cultures
SO0o Effective concn" (,ug/ml) Minimum cytotoxic50%Effe tiveoncn'(~~~~~~Wml) concnb (p.gIml)
Compound
Herpes simplex virus Herpes simplex Vaccinia Vesicular stomatitis Cell Protein
type 1 KOS virus type 2 G virus virus morphology synthesis'
Neplanocin A 7 10 0.02 0.02 .400 2.7 ± 0.9
3-Deazaneplanocin A >400 400 0.07 0.07 >400 >117
DHCA 150 300 0.7 0.2 >400 >200
DHCDA >400 200 0.7 0.2 >400 61 ± 5
C-c3Ado >400 >400 2 0.2 >400 88 ± 30
"Required to inhibit virus-induced cytopathogenicity by 50%; average values for two to three experiments.
b Required to cause a microscopically detectable alteration of normal cell morphology or to inhibit protein synthesis (based on [4,5-3HJLeu incorporation) by
50%.
' Average values + standard deviations.
of incubation of the cells in the presence of the test com-
pounds). The latter method for cytotoxicity evaluation was
carried out specifically for the MA 104 cells (used in the
rotavirus experiments).
Cytostatic activity. The cells were seeded in 96-well test
plates (at 6,000 cells per well for the AK' and AK- cells)
and in 24-well test plates (at 16,000 cells per well for the
PRK, Vero, and HeLa cells) in Eagle minimum essential
medium containing 10% fetal calf serum (horse serum for the
experiments with the AK' and AK- cells), and 4 h later,
various concentrations of the test compounds were added.
The cells were allowed to proliferate for 72 h (for the Vero
and AK+- and AK--B-mix K-44/6 cells) or 96 h (for the PRK
and HeLa cells) at 37°C in a humidified, C02-controlled
atmosphere. The growth of the cells was linear during this
period. The cells were then trypsinized and enumerated in a
Coulter counter. Cytostatic activity was expressed as the
concentration of compound required to reduce the cell
number by 50%.
Antiviral activity in vivo. The antiviral efficacy of the
compounds was assessed in an experimental model infection
that was previously developed to monitor the protective
effects of interferon and interferon inducers (10). Newborn
(2-day-old) NMRI (Naval Medical Research Institute) mice
were inoculated subcutaneously with vesicular stomatitis
virus (4 PFU [as determined in mouse L-929 cell cultures]/
0.05 ml per mouse). The mice then received either a single
intraperitoneal injection of the compound (in 0.1 ml of PBS)
at 1 h postinfection or repeated intraperitoneal injections of
the compound at 1 h postinfection (day 1) and the subse-
quent 4 days (days 2, 3, 4, and 5). Mortality was monitored
for 20 days. The mortality rates of the different treatment
groups were compared with that of the corresponding con-
trol group (which received either one or repeated injections
of PBS), and the statistical significance of the differences
was assessed by the x2 test with Yates' correction.
RESULTS
When examined for its activity against herpes simplex
virus, vaccinia virus, and vesicular stomatitis virus in PRK
cells (Table 1), neplanocin A showed 50% effective concen-
trations that were comparable to those reported previously
(6). The novel neplanocin A analogs, 3-deazaneplanocin A,
DHCA, and DHCDA, were inhibitory to vaccinia virus and
vesicular stomatitis virus at concentrations which were only
slightly higher than the 50% effective concentration of nepl-
anocin A. In contrast to neplanocin A, its new congeners
were much less toxic to host-cells (based on inhibition of
host-cell protein synthesis) (Table 1). The new neplanocin A
analogs were virtually inactive against herpes simplex virus
type 1 or 2, and, in this sense, they behaved like C-c3Ado
(11) (included as the reference compound) and other adeno-
sine analogs which have been previously recognized as
AdoHcy hydrolase inhibitors (7).
In HeLa cells, as in PRK cells, 3-deazaneplanocin A,
DHCA, and DHCDA inhibited the replication of vesicular
stomatitis virus at a concentration that was well below their
cytotoxicity threshold, whether based on cell morphology or
cellular protein synthesis (Table 2). However, the com-
pounds were much less active in HeLa cells than in PRK
cells. As could be expected from AdoHcy hydrolase in-
hibitors (7), neither 3-deazaneplanocin A, DHCA, nor
DHCDA was inhibitory to the (+)RNA viruses poliovirus
(Table 2), coxsackievirus (Tables 2 and 3), and Sindbis and
Semliki Forest viruses (Table 3). However, they were mark-
edly active against parainfluenza virus, a (-)RNA virus, and
reovirus, a double-stranded (+)RNA virus (Table 3). In Vero
cells (Table 3), 3-deazaneplanocin A, DHCA, and DHCDA
were more inhibitory to protein synthesis than in PRK
or HeLa cells, so that in Vero cells, their antiviral ac-
tivity (against reovirus and parainfluenza virus) was
TABLE 2. Antiviral activity and cytotoxicity in HeLa cell cultures"
50% Effective concn (,ug/ml) Minimum cytotoxic concn (,ug/ml)
Compound Vesicular Poliovirus Cell Protein
stomatitis virus Coxsackievirus B4 type 1 morphology synthesis
Neplanocin A 0.7 >10 >10 40 1.1 + 0.5
3-Deazaneplanocin A 10 >400 >400 >400 >129
DHCA 40 >400 >400 >400 91 ± 61
DHCDA 10 >400 >400 -400 48 ± 11
C-c3Ado 100 >400 >400 >400 103 ± 55
' See footnotes to Table 1.
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TABLE 3. Antiviral activity and cytotoxicity in Vero cell cultures"
50% Effective concn (,ug/ml) Minimum cytotoxic
concn (p.g/ml)
Compound
Parainfluenza Reovirus Sindbis Coxsackievirus Semliki Cell Protein
virus type 3 type 1 virus B4 Forest virus morphology synthesis
Neplanocin A 0.2 0.7 >10 >10 >10 .10 0.4 ± 0.1
3-Deazaneplanocin A 0.2 0.07 >400 400 >400 >400 0.3 ± 0.08
DHCA 2 0.7 >400 >200 >400 .400 4.7 ± 2
DHCDA 2 2 >400 150 >200 .400 3.6 ± 2.3
C-c3Ado 0.2 1 >400 150 >400 >400 21 ± 12
a See footnotes to Table 1.
achieved at concentrations which were only slightly below
the cytotoxicity threshold.
When neplanocin A and its congeners were examined for
their inhibitory effects on the proliferation of PRK, HeLa,
and Vero cells in their exponential growth phase, neplanocin
A and 3-deazaneplanocin A were about equally inhibitory to
PRK and HeLa cell growth, whereas 3-deazaneplanocin A
was about fivefold more inhibitory to Vero cell growth
(Table 4). Irrespective of the nature of the cells (Vero,
HeLa, or PRK), the decapitated neplanocins DHCA and
DHCDA were 10- to 100-fold less inhibitory than the parent
compounds were (Table 4), which is consistent with the
results reported previously for L-929 cells (16).
Among the double-stranded RNA viruses, rotaviruses are
particularly sensitive to the inhibitory effects of AdoHcy
hydrolase inhibitors (7, 20). This has now been confirmed for
C-c3Ado and neplanocin A (Table 5); in agreement with
earlier findings (20), these compounds inhibited rotavirus
replication at a concentration which was almost 100-fold
below their cytotoxicity threshold. Also, 3-deazaneplanocin
A, DHCA, and DHCDA proved inhibitory to rotavirus
replication at a concentration that was at least 2 orders of
magnitude lower than the cytotoxic concentration (Table 5).
3-Deazaneplanocin A inhibited rotavirus replication at a
concentration of 0.04 ,ug/ml, while not being toxic up to a
concentration of 400 ,ug/ml, thus achieving a selectivity
index of 10,000, the highest selectivity index ever reported
for a rotavirus inhibitor.
When evaluated for their inhibitory effects on the replica-
tion of HIV-1 in MT-4 cells, none of the compounds listed in
Table 6 (i.e., neplanocin A, 3-deazaneplanocin A, DHCA,
TABLE 4. Inhibitory effects on the growth of PRK, HeLa,
and Vero cells
50% Cytotoxic concn" (,ug/ml)
Compound
PRK HeLa Vero
Neplanocin A 0.12 0.08 0.17 0.1 0.25 + 0.17
3-Deazaneplanocin A 0.14 0.05 0.31 0.2 0.05 0.03
DHCA 9.0 6.5 18 15 1.1 0.6
DHCDA 8.9 2.9 5.6 4 2.2 2
C-c3Ado 17 10 1.3 + 0.7 0.33 0.1
a Required to inhibit cell growth (after 3 days for Vero cells and 4 days for
PRK and HeLa cells) by 50%. The data represent average values ± standard
deviations for four or more experiments.
DHCDA, and C-c3Ado) proved effective at nontoxic con-
centrations. In fact, neplanocin A and 3-deazaneplanocin A
were highly toxic for MT-4 cells (50% cytotoxic doses, 0.016
and 0.025 ,ug/ml, respectively).
If the antiviral effects of neplanocin A and its congeners
are mediated by inhibition of AdoHcy hydrolase, the agents
do not need to be phosphorylated by AK to achieve their
antiviral activity, and, therefore, they may be expected to be
antivirally active in AK- cells. A paired AK+-AK- cell
system (5) was established to determine the role ofAK in the
antiviral activity of the adenosine analogs. As shown in
Table 7, neplanocin A, 3-deazaneplanocin A, DHCA, and
DHCDA were fully active against vaccinia virus and vesic-
ular stomatitis virus in AK- cells and their 50% effective
doses were equal to or only slightly higher than those
recorded in AK' cells. In contrast, various other adenosine
analogs such as tubercidin, xylotubercidin, sangivamycin,
toyocamycin, and cordycepin, which are assumed to act
primarily as their phosphorylated products and thus depend
on AK for their metabolic conversion, were significantly less
active in AK- than AK' cells. This differential activity was
particularly striking for tubercidin, which was inhibitory to
vaccinia virus and vesicular stomatitis virus in AK- cells at
a concentration that was more than 1,000-fold higher than
that required to inhibit the same viruses in AK' cells (Table
7).
The role of AK in the biological activity of the adenosine
analogs was further explored by direct comparison of their
50% inhibitory doses (ID50s) for the growth of AK' and
AK- cells. In all cases, the ID50 for AK- cell growth was
higher than the ID50 for AK' cell growth (Table 8), but,
TABLE 5. Activity against rotavirus in MA 104 cell cultures
50% Effective Minimum SelectivityCompound concn" /1ml) cytotoxic index'(~g concnb (p.g/ml)
Neplanocin A 0.2 14 70
3-Deazaneplanocin A 0.04 400 10,000
DHCA 0.5 > 100 >200
DHCDA 1.0 > 100 >100
C-c3Ado 1.4 >100 70
" Required to effect a 90% reduction in virus yield. The virus strain used
was MO (subgroup 2. serotype 3).
"Required to reduce viable cell counts by 50%.
Ratio of minimum cytotoxic concentration to minimum (antivirally) effec-
tive concentration.
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TABLE 6. Activity against HIV-1 in MT-4 cell cultures
Compound 50% Effective 50% Cytotoxic Selectivityconcn' (jig/ml) concnb (j,g/ml) index"
Neplanocin A >0.016 0.016 <1.0
3-Deazaneplanocin A >0.025 0.025 <1.0
DHCA >0.9 0.9 <1.0
DHCDA >3.3 3.3 <1.0
C-c3Ado >1.1 1.1 <1.0
a Required to inhibit virus-induced cytopathogenicity by 50%.
b Required to reduce the number of living MT-4 cells by 50%.
Ratio of 50% cytotoxic concentration to 50% (antivirally) effective con-
centration.
while the ratio of the ID50 for AK- cell growth to the ID50 for
AK' cell growth did not exceed 1 order of magnitude for the
neplanocin A congeners, it went up to 3 orders of magnitude
for tubercidin, toyocamycin, and cordycepin. Again, these
results point to the need for phosphorylation of the latter
adenosine analogs by AK, whereas such phosphorylation is
of lesser importance for the biological activity of the nepl-
anocin A analogs.
Because of their potency against vesicular stomatitis virus
in cell culture (Table 1), the neplanocin A analogs were
further investigated for their activity against a lethal vesicu-
lar stomatitis virus infection in mice, i.e., newborn mice
inoculated subcutaneously with vesicular stomatitis virus. In
this model (10), neplanocin A does not offer any protection
(6). 3-Deazaneplanocin A, however, conferred a highly
significant reduction in the mortality rate when administered
as a single dose of 0.5 or 2.5 mg/kg per day (1 h postinfection)
or repeated doses of 0.5 mg/kg per day (1 h and 2, 3, and 4
days postinfection) (Fig. 2). At lower doses (0.1 mg/kg per
day) and higher doses (2.5 mg/kg per day [five times], 10
mg/kg per day, and 50 mg/kg per day), it was not protective
(Table 9). At these higher doses, 3-deazaneplanocin A was
also toxic to the mice (data not shown). DHCA offered some
protective activity, but only at a dose of 0.5 mg/kg per day,
given singly or repeatedly (Table 9). At a dose of 2.5 mg/kg
per day (or higher) it was toxic (data not shown). For
DHCDA there was only a hint of activity, if administered at
a dose of 0.5 mg/kg per day (Table 9).
TABLE 7. Antiviral activity in AK+- and AK--B-mix
K-44/6 cell cultures
50% Effective concn" (iig/ml)
Compound Vesicular stomatitis virus Vaccinia virus
AK' cells AK- cells AK' cells AK- cells
Neplanocin A 0.007 0.002 0.002 0.007
3-Deazane- 0.04 0.2 0.007 0.07
planocin A
DHCA 0.2 1 0.2 0.2
DHCDA 0.7 4 0.7 0.7
Tubercidin 0.007 10 0.004 (tox) 7
Xylotubercidin 1 (tox) >400 >4 (tox) >100
Sangivamycin 0.1 (tox) 10 (tox) 0.1 (tox) 0.7
Toyocamycin 0.4 (tox) 4 (tox) 0.1 (tox) 0.7
Cordycepin 0.7 >200 0.1 (tox) >200
" Required to inhibit virus-induced cytopathogenicity by 50%. The values
are averages for two to three experiments. Where the indicated value is
followed by (tox), microscopically visible cytotoxicity was observed at the
minimum (antivirally) effective concentration.
TABLE 8. Cytostatic activity against AK+- and
AK--B-mix K-44/6 cells
Compound 50% Inhibitory concn" (pLg/ml) Ratio'
AK' cells AK- cells
Neplanocin A 0.0054 ± 0.0013 0.02 ± 0.012 3.7
3-Deazaneplanocin A 0.036 ± 0.011 0.40 ± 0.08 11
DHCA 1.3 ± 0.8 8.8 ± 2.2 6.8
DHCDA 3.3 ± 0.9 20.6 ± 7.8 6.2
Tubercidin 0.036 ± 0.016 14 ± 7.3 389
Xylotubercidin 3.7 ± 1.2 >500 >135
Sangivamycin 0.031 ± 0.015 5.2 ± 0.9 168
Toyocamycin 0.0030 ± 0.0005 2.6 ± 0.8 867
Cordycepin 0.030 ± 0.019 72 ± 19 2,400
" Required to inhibit cell growth (after 3 days) by 50%. The data represent
average values ± standard deviations for at least four separate determina-
tions.
" Ratio of 50% inhibitory concentration for AK- cell growth to 50%
inhibitory concentration for AK' cell growth.
DISCUSSION
3-Deazaneplanocin A, DHCA, and DHCDA were synthe-
sized with the intent of developing agents with greater
selectivity as AdoHcy hydrolase inhibitors or antiviral
agents (13, 16). This expectation was fulfilled in that 3-
deazaneplanocin A, DHCA, and DHCDA were indeed more
selective in their antiviral action than neplanocin A was.
This higher selectivity is particularly evident when the
concentrations required for inhibition of vesicular stomatitis
virus replication are compared with those that are needed
to inhibit cellular protein synthesis (Tables 1 and 2). On
the basis of these data, 3-deazaneplanocin A, DHCA, and
DHCDA would attain a selectivity index (ratio of the mini-
mum cytotoxic concentration to the 50% effective dose) of 3
orders of magnitude (Table 1). Even more remarkable is the
selectivity of 3-deazaneplanocin A against rotavirus, for
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FIG. 2. Inhibitory effect of 3-deazaneplanocin A on the mortality
of NMRI mice inoculated subcutaneously when 48 h old with
vesicular stomatitis virus. 3-Deazaneplanocin A was administered
intraperitoneally at the following dosage regimens: 2.5 mg/kg at 1 h
postinfection (A); 0.5 mg/kg at 1 h postinfection (V); and 0.5 mg/kg
at 1 h (day 1) and on days 2, 3, 4, and 5 (0). Control PBS, One
injection at 1 h postinfection (A) or five injections at 1 h (day 1) and
on days 2, 3, 4, and 5 (0).
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TABLE 9. Effects of 3-deazaneplanocin A, DHCA, and DHCDA
on the mortality rate of NMRI mice infected subcutaneously
when 48 h old with vesicular stomatitis virus
Dose Time oftreatmenth Mortal- Signifi-Compound," (mg/kg (h or days ity' cance"l
per day) postinfection)
3-Deazaneplanocin A 50 1, 2, 3, 4, 5 10/10e NS
1 10/10e NS
10 1, 2, 3, 4, 5 10/10" NS
1 9/10" NS
2.5 1, 2, 3, 4, 5 18/20e NS
1 10/40 P < 0.001
0.5 1,2,3,4,5 8/30 P<0.001
1 10/30 P < 0.001
0.1 1,2,3,4,5 9/10 NS
DHCA 50 1, 2, 3, 4, 5 10/10e NS
1 ioiioe NS
10 1, 2, 3, 4, 5 iolloe NS
2.5 1, 2, 3, 4, 5 iollie NS
1 19/20e NS
0.5 1, 2, 3, 4, 5 25/30 P < 0.02
1 31/40 P < 0.05
0.1 1, 2, 3, 4, 5 20/20 NS
1 20/20 NS
DHCDA 10 1 9/1Oe NS
2.5 1, 2, 3, 4, 5 19/20e NS
1 19/20" NS
0.5 1, 2, 3, 4, 5 17/20 P < 0.05
1 16/20 NS
Placebo 1, 2, 3, 4, 5 69/70
1 47/50
"Injected intraperitoneally.
b If treatment consisted of only one injection, it was administered 1 h
postinfection (indicated by 1); if treatment consisted of five repeated injec-
tions, they were administered at 1 h postinfection (day 1) and on days 2, 3, 4,
and 5 (indicated by 1, 2, 3, 4, 5).
' Mortality was monitored until day 20 postinfection.
d As compared to the corresponding control (placebo group) which received
either one injection of PBS or five injections of PBS. Significance was
assessed by the x2 test with Yates' correction. NS, Not significant.
eMortality due to toxicity of the compound.
The antiviral activity spectrum of 3-deazaneplanocin A,
DHCA, and DHCDA is similar to that of neplanocin A (6),
C-c3Ado (11), and the other adenosine analogs that have
been previously recognized as AdoHcy hydrolase inhibitors
(7). This spectrum includes, in addition to the viruses that
were found to be susceptible to the neplanocin A analogs in
the present study (vaccinia, vesicular stomatitis, parainflu-
enza, reo-, and rotaviruses), African swine fever, measles,
rabies, and several plant viruses. It seems imperative to
further examine 3-deazaneplanocin A, DHCA, and DHCDA
for their activity against these viruses.
In contrast, neither neplanocin A nor 3-deazaneplanocin
A, DHCA, DHCDA, or C-c3Ado caused a selective inhibi-
tion of HIV replication in MT-4 cells. Yet, treatment of
MT-4 cells with neplanocin A (1 to 10 ,uM) increased
intracellular AdoHcy levels 5- to 10-fold and reduced
AdoHcy hydrolase activity to 1 to 2% (data not shown).
Also, DHCA, DHCDA, and C-c3Ado are assumed to
achieve their antiviral and anticellular effects through inhi-
bition ofAdoHcy hydrolase. Since none of these compounds
proved to be active against HIV, one may infer that the
replication of HIV, unlike the reduction of the other viruses
mentioned above, is not influenced by an increase in
AdoHcy levels. Thus, AdoHcy hydrolase does not appear to
be an appropriate target for the design of anti-HIV agents.
3-Deazaneplanocin A, DHCA, and DHCDA are potent
inhibitors of AdoHcy hydrolase (13, 17, 22), and their
antiviral effects can be attributed to inhibition of the enzyme.
With a series of four compounds [(S)-9-(2,3-dihydroxypro-
pyl)adenine, (RS)-3-adenin-9-yl-2-hydroxypropanoic acid,
C-c3Ado, and neplanocin A], a close correlation (r = 0.986)
was found between antiviral potency (against vesicular sto-
matitis virus) and inhibitory effects on (bovine liver)
AdoHcy hydrolase (9). With an extended number of com-
pounds, now also including adenosine dialdehyde and 3-
deazaneplanocin A, an even better correlation (r = 0.993)
was found between potency against vaccinia virus and
inhibitory effects on L-929 cell AdoHcy hydrolase (4). This
close correlation points to AdoHcy hydrolase as the target
for the antiviral action of these adenosine analogs.
From a mechanistic viewpoint, the present results rein-
force the concept that neplanocin A and its congeners owe
their antiviral activity to inhibition of AdoHcy hydro-
lase. The fact that the decapitated analogs DHCA and
DHCDA, which lack the 4'-hydroxymethyl group that would
otherwise make them substrates for AK, were more selec-
tive in their antiviral action than neplanocin A was clearly
indicates that the compounds are active per se and do not
have to be phosphorylated to acquire antiviral activity. Also,
the neplanocin A analogs did not lose much of their antiviral
or cytostatic potential in AK cells relative to the corre-
sponding AK' cells (Tables 7 and 8), which again indicates
that any phosphorylation by the AK would be superfluous
for their antiviral or cytostatic action.
From a therapeutic viewpoint, it is evident that 3-deaza-
neplanocin A, DHCA, and DHCDA should be further pur-
sued for their in vivo efficacy in the appropriate animal
models. In one such model, in which mortality of newborn
mice was monitored after a lethal infection with vesicular
stomatitis virus, 3-deazaneplanocin A provided a highly
significant protection (Fig. 2) over a narrow dosage range
(0.5 to 2.5 mg/kg per day) (Table 9). With DHCA and
DHCDA, little efficacy was noted at the subtoxic dose (0.5
mg/kg per day). To obtain a better insight into the clinical
potential of the compounds, these studies should be ex-
tended to other treatment regimens (e.g., treatment started
late postinfection) and other animal models (e.g., rota and
rabies).
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